AllSci News
Qyuns picks up milestone from Roche as TSLP/IL-33 BsAb enters clinic
Roche has received the first clinical milestone under its global exclusive licensing agreement with Qyuns Therapeutics (HKEX: 2509), triggered by the dosing...
XtalPi receives USD 19m second payment from DoveTree under USD 5.89b AI drug discovery deal
XtalPi Holdings (HKEX: 2228) has received a second payment of USD 19 million from DoveTree under their AI-driven drug discovery collaboration, bringing...
D&D Pharmatech's GLP-1/glucagon dual agonist hits Phase II endpoints in MASH
D&D Pharmatech (Kosdaq: 347850) has reported 48-week histology data from its Phase II trial of zabopegdutide in metabolic dysfunction-associated...
Precision Bio's PBGENE-HBV demonstrates direct cccDNA elimination in chronic hepatitis B trial
Precision BioSciences (Nasdaq: DTIL) reported the first clinical evidence of direct cccDNA elimination in liver biopsies from patients with chronic...
NEOK Bio doses first patients in Phase I trials of dual bispecific ADCs targeting B7-H3/ROR1 and EGFR/MUC1
NEOK Bio doses first patients in Phase I trials of dual bispecific ADCs targeting B7-H3/ROR1 and EGFR/MUC1
Sobi's olezarsen reduces acute pancreatitis risk by 85% in severe hypertriglyceridemia
Sobi (STO: SOBI) has reported that olezarsen (Tryngolza) reduced the relative risk of acute pancreatitis by 85% and lowered triglycerides by 66% in a pooled...
Corcept bounces back from CRL to resubmit relacorilant NDA for Cushing's syndrome
Corcept Therapeutics (Nasdaq: CORT), based in Redwood City, California, plans to resubmit its New Drug Application to the US FDA for relacorilant as a...
Protuoso Bio backed with USD 9.5m seed funding for fusion protein platform
San Carlos-based Protuoso Biosciences announced the close of an oversubscribed USD 9.5 million seed financing round to advance its MUXBODY fusion protein...
Jade Bio starts first human study for BAFF-R antibody JADE201 in rheumatoid arthritis
Jade Biosciences (Nasdaq: JBIO), a San Francisco-based clinical-stage biotechnology company, has dosed the first participant in a first-in-human Phase I...
Editas prices USD 319m offering as EDIT-401 gene therapy for hyperlipidemia progresses
Cambridge, Massachusetts-based Editas Medicine (Nasdaq: EDIT) has announced the pricing of an underwritten public offering of common stock and accompanying...
Assembly follows Gilead option exercise with USD 115m share offering
South San Francisco-based Assembly Biosciences (Nasdaq: ASMB) has closed an underwritten registered public offering of common stock and pre-funded warrants,...
Hansa Biopharma's imlifidase achieves 90% graft survival in kidney transplant desensitization study
Hansa Biopharma (Nasdaq Stockholm: HNSA) has reported that imlifidase (Idefirix) achieved 90% one-year graft failure-free survival in a post-authorization...
Nanobiotix closes USD 100m global offering to advance Nanoprimer platform
Paris-based Nanobiotix (Euronext: NANO; Nasdaq: NBTX), a late-stage clinical biotechnology company developing physics-based cancer therapies, has closed a...
Cartesian Therapeutics secures USD 150m in credit to fund BCMA CAR-T ahead of Phase III data
Frederick, Maryland-based Cartesian Therapeutics (Nasdaq: RNAC) has announced a non-dilutive credit facility of up to USD 150 million with K2 HealthVentures...
Foresee's leuprolide mesylate achieves 94% LH suppression in Phase III central precocious puberty trial
Foresee Pharmaceuticals (TPEx: 6576) reported that 94% of children with central precocious puberty achieved LH suppression to prepubertal levels in its...
The AllSci Brief
Systematic R&D and deal news. Daily.